$CBIH Balance Sheet | Understand Stock

$CBIH

$0.00 +$0.00 (0.0%) Close

$CBIH Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2026 As of Feb 28, 2026	Q2 FY2026 As of Nov 30, 2025	Q1 FY2026 As of Aug 31, 2025	Q4 FY2025 As of May 31, 2025	Q1 FY2025 As of Aug 31, 2024	Q4 FY2024 As of May 31, 2024	Q3 FY2024 As of Feb 29, 2024	Q2 FY2024 As of Nov 30, 2023	Q3 FY2012 As of Feb 29, 2012	Q2 FY2012 As of Nov 30, 2011
ASSETS
Restricted cash
Cash and cash equivalents
Accounts receivable
Other receivables
Inventories
Related party receivables
Related-party receivables
Other current assets
TOTAL CURRENT ASSETS
Property, plant and equipment, net
Prepayments
Accounts receivable, net - long-term
Deferred tax assets
Other receivables - long-term
Total long-term assets
Right-of-use asset
TOTAL ASSETS

Trade accounts payable
Related party payable
Other payables
Current portion of capital lease obligations
Accrued expenses
Tax payable
Bank loan payable
CURRENT LIABILITIES
Accounts payable and accrued expenses
Bank overdraft
Deferred revenue
Related party payables
Deferred revenues
Credit cards
Accrued interest
Related-party payables
Short-term loans (net of amortization of loan fees)
SBA loans
PPP loan
Derivative liabilities
Lease liabilities
Convertible note
TOTAL CURRENT LIABILITIES
LONG-TERM LIABILITIES
Long-term portion of capital lease obligations
Notes payable
SBA loans
Lease liabilities

TOTAL LONG-TERM LIABILITIES
TOTAL LIABILITIES
STOCKHOLDERS’ DEFICIENCY
Authorized: 10,000,000 shares of preferred stock, without par value, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock (2,500,000 shares outstanding at February 28, 2026, and May 31, 2025) and 2,000 shares have been designated Series B Preferred Stock (2,000 shares outstanding at February 28, 2026, and May 31, 2025)
Common Stock, without par value: 20,000,000,000 shares authorized, of which 11,626,749,347 shares were issued and outstanding at February 28, 2026, and May 31, 2025
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income

TOTAL STOCKHOLDERS’ DEFICIENCY
Non-controlling interests
TOTAL EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

Comments